L
Livnat Bangio
Publications - 25
Citations - 377
Livnat Bangio is an academic researcher. The author has contributed to research in topics: Genetic enhancement & Angiogenesis. The author has an hindex of 11, co-authored 25 publications receiving 365 citations.
Papers
More filters
Journal ArticleDOI
Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I.
Jacob George,Niva Yacov,Eyal Breitbart,Livnat Bangio,Aviv Shaish,Boris Gilburd,Yehuda Shoenfeld,Dror Harats +7 more
TL;DR: Testing the hypothesis, that inhibiting cellular immunity to beta 2GPI would result in suppression of fatty streak formation in mice found that oral administration of beta 2 GPI is an effective means of suppressing atherogenesis in mice.
Journal ArticleDOI
Transcription-controlled gene therapy against tumor angiogenesis
Shoshana Greenberger,A. Shaish,A. Shaish,Nira Varda-Bloom,Nira Varda-Bloom,Keren Levanon,Keren Levanon,Eyal Breitbart,Iris Goldberg,Iris Goldberg,Iris Barshack,Iris Barshack,Israel Hodish,Israel Hodish,Niva Yaacov,Livnat Bangio,Tanya Goncharov,David Wallach,Dror Harats,Dror Harats +19 more
TL;DR: Evidence that transcriptionally controlled, angiogenesis-targeted gene therapy is feasible is provided, using adenoviral vector-mediated delivery of a chimeric death receptor derived from the modified endothelium-specific pre-proendothelin-1 (PPE-1) promoter.
Patent
Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
TL;DR: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
Journal ArticleDOI
Endothelial-targeted Gene Transfer of Hypoxia-inducible Factor-1α Augments Ischemic Neovascularization Following Systemic Administration.
Reshef Tal,Aviv Shaish,Karen Rofe,Erez Feige,Nira Varda-Bloom,Arnon Afek,Iris Barshack,Livnat Bangio,Israel Hodish,Shoshana Greenberger,Michael Peled,Eyal Breitbart,Dror Harats +12 more
TL;DR: Data suggest that transcriptionally controlled systemic proangiogenic gene therapy is feasible, safe, and efficacious for HIF-1α administration.
Journal ArticleDOI
Activation of C-transactivation domain is essential for optimal HIF-1α-mediated transcriptional and angiogenic effects
TL;DR: In-vitro angiogenesis assay using transfected human umbilical vein endothelial cells (HUVEC) showed that TM stimulated tube formation to a greater extent than both P402A P564G mutant and wild-type HIF-1 alpha, and ELISA revealed that VEGF levels within thetransfected HUVEC were about 10-fold greater with the TM.